Crossmark

Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances—Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam—in the UK

Crossref DOI link: https://doi.org/10.1007/s13181-018-0659-3

Published Online: 2018-04-18

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abouchedid, Rachelle

Gilks, Thea

Dargan, Paul I

Archer, John R. H

Wood, David M
License Information

Text and Data Mining valid from 2018-04-18
More Information

Article History

Received: 4 August 2017

Revised: 3 March 2018

Accepted: 27 March 2018

First Online: 18 April 2018

Compliance with Ethical Standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below